U.S. Markets close in 5 hrs 52 mins

Galena Biopharma, Inc. (GALE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3549+0.0049 (+1.4000%)
As of 10:06AM EDT. Market open.
People also watch
IMUCCYTRCLDXINOTHLD
  • i
    ignatius
    ignatius

    Stock Invest.us Analysis:
    https://stockinvest.us/technical-analysis/GALE

    Trend
    "Galena Biopharma lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -45.31% during the next 3 months and, with 90% probability hold a price between $0.11 and $0.22 at the end of this period."

    Signals
    "There are few to none technical positive signals at the moment. Galena Biopharma holds sell signals from both short- and long-term moving averages. In addition, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. A sell signal was issued from a pivot top point on Friday September 15, 2017, which indicates further falls until a new bottom pivot has been found. Galena Biopharma gained volume on the last day, but on falling prices. In technical terms this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-off's".

  • B
    Bone
    Bone
    Galena has already proven that everything Ahn bought was dumpster junk.
    Abstral was a dud and had to be disposed at a loss.
    Zuplenz underwhelmed and it too was disposed at a loss.
    Neuvax, in a Data Mined trial, failed as expected.
    Need more proof, Carlos? The Galena shell has nothing more to prove.
    Management orchestrated the DreamTeam Pump & Dump scheme, filled their pockets and left the baggies with worthless bags.
  • L
    Louis
    Louis
    A 1 for 30 REVERSE STOCK SPLIT is good news?
  • n
    nice
    nice
    DD for Carlos (from Galena's filed Form 8-K:

    "Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), (a) each outstanding share of SELLAS (excluding shares held by Galena, Merger Sub or SELLAS and dissenting shares) will be converted into the right to receive shares of Galena Common Stock based on an exchange ratio specified in the Merger Agreement after giving effect to the REVERSE STOCK SPLIT discussed below

    an amendment of Galena’s certificate of incorporation to effect the REVERSE STOCK SPLIT at a ratio of 30-for-one or as otherwise mutually agreed by Galena and SELLAS;
  • f
    flnn
    flnn
    Do some DD on stocks headed for a reverse split. The catastrophe that you are viewing is called Galena. You have no clue but keep spouting off. You've already lost your shirt on this turd stock. Your little boy pants are next:).
  • j
    jenny
    jenny
    Why would the shorts be gone at the time of the merger? The stock dropped a lot since the merger was announced. So the merger is not viewed as a positive for Galena shareholders. About 80 million additional shares will be issued in the merger, so the volume should increase after the merger thereby making it easier for the shorts to cover. But, they will probably wait for the next next dilutive offering and cover with the discounted shares. With the pending reverse stock split, they may choose not to cover. Stocks tank badly after reverse splits. The shorts will be gone with your money, Carlos. That is the good news.
  • d
    david
    david
    Is a 1 for 30 REVERSE STOCK SPLIT considered good news?
  • m
    million dollar
    million dollar
    I guess you need James to justify your stupidity. Down over 50% since listening to James makes you the loser.
  • B
    Bone
    Bone
    Carlos, your crying is just beginning. More pain to come. Apply vaseline on your butt.
  • S
    Sayed
    Sayed
    RED again, like Carlos' butt?
  • p
    pernn
    pernn
    Carlos deserve a thumbs down. All he does is cry and name call like a five year old. He got scammed into a turd stock, on the verge of a 1 for 30 Reverse Stock Split. Not too smart!
  • m
    mass
    mass
    Carlos will be contacting bankruptcy court soon. It will be over for him soon, the poor sad sap.
  • P
    Pine
    Pine
    CAUTION!!!!!
    Ghiglieri, The Undertaker...............................
    Ghiglieri was the CFO at Hansen Medical. The stock plunged from $375.00 and the Company was sold for $3.99 per share.
    Ghiglieri was the CFO and COO at NeurogesX for 10 years. The stock dropped from $10.00 to $0.005 and closed up shop after completing a $20M private placement and blowing all the funds.
    Sound familiar?
  • B
    Bone
    Bone
    Carlos, you don't like the truthful posts. You just want to see pump posts on sketchy stocks.
    GALE and INO deserved to be bashed. GALE tanked from $155 to $0.35. INO tanked from $200 to $6.
    This all transpired during a strong bull market.
    Thankfully somebody exposed these putrid stocks and some mom and pops were dissuaded from buying and losing their hard earned money to scammers pumping these scams as great investments.
    This post took me a couple of minutes. That's a full time job for you?
    James and DopeyDan pumped GALE day and night. They even set up a website, mygale, to pump GALE.
    That sounds like a full time endeavor but you are not taking issue with the scammers who cost mom and pops nearly a $billion on the GALE pump & dump operation, which even conned you into a 50% loss. WHY IS THAT, CARLOS?
    You can't face the fact that you are a gullible sap who got sucked in by scammer James so you are lashing out at those who have been right and cautioned you about this scam stock? IS THAT IT?
  • m
    million dollar
    million dollar
    GALE down again and headed for a 1 for 30 Reverse Split. The shorts must be panicking. Right, Carlos? LoLoLoLoL
  • P
    Pine
    Pine
    A post from James last year:
    "Neuvax 100% Chance of Success. A 70th breast cancer recurrence event in late March 2016 thus predicts (1) no possibility of NeuVax efficacy equaling 30% or less (the minimum Special Protocol Assessment threshold required for approval by the FDA.
    A simple go to completion - imminent - will be jumping GALE PPS as it puts Neuvax firmly on track for FDA Approval and commercialization with Projected REvs in excess of $2b. This would generate a Market Cap in the Tens of Billions."
    Is James a boiler room scammer?
  • B
    BlockbusterPicks
    BlockbusterPicks

    MDNA.TO (MC C$36 M) (Cash C$20 M) Hot Cancer Play with important Results in Q1 that could lead to FDA approval =1500-2000% UPSIDE Potential ! RALLYYYYYYYYYYY

    Brutally cheap and completely unknown canadian biotech stock with minimum 10 bagger potential . Positive Phase 2 results in recurrent glioblastoma which expected in Q1 2018 could lead to accelerated approval which would be a HUGE MAJOR milestones for this undiscovered low float stock . This company has brutally low valuation of only $36 million and most of that in cash $20 million which is enough untill Q1 2019 . This stock at $1.50 is a lifetime opportunity and we could see $15-20 easily on Positive 2 results and FDA approval .GL

    Medicenna Therapeutics (MDNA.TO)

    Market Cap C$36 Million
    Cash : C$ 20 Million << enough untill Q1 2019
    Price : $1.50

    Shares Out: 24.3 Million ( 15.5 Million shares held by Insider alone )

    Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval
    https://smallcappower.com/videos/companies-to-watch/medicenna-therapeutics-tsxv-mdna/

    New Presentation
    http://s21.q4cdn.com/710416940/files/doc_presentations/2017/Medicenna-Corporate-Presentation-Q3-2017.pdf

    Fact Sheet
    http://s21.q4cdn.com/710416940/files/doc_downloads/fact_sheet/Medicenna-FS-Q1-2017-v2.pdf

    Insider Ownership :

    Aries Biologics, Inc. 5 500 000
    Rosemina Merchant 5 050 000
    Fahar Merchant 5 050 000
    Elizabeth Williams 5 300
    Chandrakant J. Panchal, PhD 1 000
    Trevor P. Wong-Chor 714

    Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval
    Medicenna Therapeutics Corp. (CVE:MDNA) President & CEO Fahar Merchant said the Company received a large grant from the state of Texas.
    smallcappower.com
  • m
    million dollar
    million dollar
    Neuvax is the failed drug. It failed in trial for Apthera. They dumped it for $7M. Galena then ran a Data Mined trial and had the DreamTeam pump Neuvax, which was sure to fail again, to gullible saps while the insiders bailed.
    Carlos: "Neuvax was doing his job". Neuvax is a failed drug not a person. Do some DD. Don't just sop up what scammers like James pump.
  • d
    david
    david
    Cry baby Carlos, had you listened to Philip, you wouldn't have lost half your money on this scam stock.
    What is your beef with Philip? HELLO!!!! James is the one who conned you into a bag.
    Ask James to return your money. Go on the mygaledung website and ask him.
    DopeyDan and James established that website to exclusively pump GALE to unsuspecting saps like you.
  • P
    Pine
    Pine
    A post from last year, titled "Three Vital Sentences", while James was pumping this dung stock:

    "Wouldn’t it be great if every biotechnology company that failed a clinical trial could remove the patients who caused the study to fail and only focus on the select few that showed some level of improvement?

    That’s exactly what Galena has done!NeuVax was tested on 187 patients – but 137 patients are being removed from the failed study so Galena can focus on 50 who did not redevelop breast cancer.

    Naturally, if breast cancer’s recurrence rate is only 20% then surely Galena could find 50 from 187 who didn’t redevelop the disease – but it doesn’t mean that NeuVax was the cause."

    James claimed 100% certitude of Neuvax approval, even fast track. Who was right? Who was conning moms and pops into overpriced bags?